Loading...

ChromoGenics

OM:CHRO BTA
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CHRO BTA
OM
SEK36M
Market Cap
  1. Home
  2. SE
  3. Capital Goods
Company description

ChromoGenics AB provides dynamic glass with controllable heat and light transmission in Sweden and internationally. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
CHRO BTA Share Price and Events
7 Day Returns
0.6%
OM:CHRO BTA
1.1%
SE Building
2.6%
SE Market
1 Year Returns
-
OM:CHRO BTA
14.8%
SE Building
4%
SE Market
CHRO BTA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ChromoGenics (CHRO BTA) 0.6% -1.4% - - - -
SE Building 1.1% 5.1% 22.8% 14.8% 29% 85.1%
SE Market 2.6% 2% 11.9% 4% 12.8% 22.5%
1 Year Return vs Industry and Market
  • No trading data on CHRO BTA.
  • No trading data on CHRO BTA.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is ChromoGenics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether ChromoGenics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as ChromoGenics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ChromoGenics. This is due to cash flow or dividend data being unavailable. The share price is SEK0.684.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ChromoGenics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ChromoGenics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OM:CHRO BTA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-1.83
OM:CHRO Share Price ** OM (2019-03-19) in SEK SEK0.81
Sweden Building Industry PE Ratio Median Figure of 11 Publicly-Listed Building Companies 16.69x
Sweden Market PE Ratio Median Figure of 322 Publicly-Listed Companies 17.04x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ChromoGenics.

OM:CHRO BTA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:CHRO Share Price ÷ EPS (both in SEK)

= 0.81 ÷ -1.83

-0.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ChromoGenics is loss making, we can't compare its value to the SE Building industry average.
  • ChromoGenics is loss making, we can't compare the value of its earnings to the Sweden market.
Price based on expected Growth
Does ChromoGenics's expected growth come at a high price?
Raw Data
OM:CHRO BTA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Sweden Building Industry PEG Ratio Median Figure of 8 Publicly-Listed Building Companies 1.23x
Sweden Market PEG Ratio Median Figure of 234 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ChromoGenics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ChromoGenics's assets?
Raw Data
OM:CHRO BTA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK-0.92
OM:CHRO Share Price * OM (2019-03-19) in SEK SEK0.81
Sweden Building Industry PB Ratio Median Figure of 13 Publicly-Listed Building Companies 2.08x
Sweden Market PB Ratio Median Figure of 562 Publicly-Listed Companies 2.48x
OM:CHRO BTA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:CHRO Share Price ÷ Book Value per Share (both in SEK)

= 0.81 ÷ -0.92

-0.88x

* Primary Listing of ChromoGenics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ChromoGenics has negative assets, we can't compare the value of its assets to the SE Building industry average.

Next steps:

  1. Take a look at our analysis of CHRO BTA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through ChromoGenics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Building industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess ChromoGenics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Building industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Building industry average (and greater than 0)? (1 check)
  5. ChromoGenics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ChromoGenics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ChromoGenics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27.6%
Expected Building industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ChromoGenics expected to grow at an attractive rate?
  • Unable to compare ChromoGenics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare ChromoGenics's earnings growth to the Sweden market average as no estimate data is available.
  • Unable to compare ChromoGenics's revenue growth to the Sweden market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OM:CHRO BTA Future Growth Rates Data Sources
Data Point Source Value (per year)
Sweden Building Industry Earnings Growth Rate Market Cap Weighted Average 27.6%
Sweden Building Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 8.5%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OM:CHRO BTA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OM:CHRO BTA Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 11 -63 -73
2018-09-30 5 -63 -70
2018-06-30 9 -58 -71
2018-03-31 8 -54 -65
2017-12-31 7 -55 -57
2017-09-30 6 -47 -49
2017-06-30 4 -46 -46
2017-03-31 4 -45 -50
2016-12-31 3 -40 -49
2016-09-30 3 -37 -51

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if ChromoGenics is high growth as no earnings estimate data is available.
  • Unable to determine if ChromoGenics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OM:CHRO BTA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from ChromoGenics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:CHRO BTA Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -1.83
2018-09-30 -2.12
2018-06-30 -2.52
2018-03-31 -2.76
2017-12-31 -3.17
2017-09-30 -2.96
2017-06-30 -3.66
2017-03-31 -6.29
2016-12-31 -7.60
2016-09-30 -6.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ChromoGenics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of CHRO BTA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. ChromoGenics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Capital Goods companies here
  3. ChromoGenics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess ChromoGenics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ChromoGenics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ChromoGenics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ChromoGenics's growth in the last year to its industry (Building).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ChromoGenics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ChromoGenics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ChromoGenics's 1-year growth to the SE Building industry average as it is not currently profitable.
Earnings and Revenue History
ChromoGenics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ChromoGenics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:CHRO BTA Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 11.24 -73.44 31.09 19.19
2018-09-30 5.17 -70.41 29.85 15.56
2018-06-30 8.50 -71.40 29.49 16.07
2018-03-31 7.71 -65.20 27.29 14.62
2017-12-31 6.86 -57.22 20.54 14.15
2017-09-30 6.34 -49.02 16.79 14.96
2017-06-30 4.04 -45.68 14.03 17.28
2017-03-31 4.06 -50.45 12.84 21.81
2016-12-31 3.04 -49.49 11.75 26.05
2016-09-30 2.79 -50.83 10.97 31.08
2015-12-31 -43.54 6.69 37.05
2014-12-31 -31.79 7.39 24.57
2013-12-31 -37.40 5.48 32.50

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ChromoGenics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if ChromoGenics has efficiently used its assets last year compared to the SE Building industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ChromoGenics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ChromoGenics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Building industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ChromoGenics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ChromoGenics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ChromoGenics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ChromoGenics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • ChromoGenics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of ChromoGenics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • ChromoGenics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ChromoGenics Company Filings, last reported 2 months ago.

OM:CHRO BTA Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -39.90 49.67 7.52
2018-09-30 -17.00 49.67 12.48
2018-06-30 -5.27 49.67 29.42
2018-03-31 11.10 49.67 48.27
2017-12-31 7.49 49.33 38.46
2017-09-30 27.36 49.67 56.70
2017-06-30 40.89 49.67 66.96
2017-03-31 51.50 49.67 82.51
2016-12-31 -36.01 63.67 8.52
2016-09-30 -30.59 54.67 2.11
2015-12-31 -10.51 49.67 10.92
2014-12-31 7.88 42.17 34.88
2013-12-31 28.42 34.67 56.29
  • ChromoGenics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if ChromoGenics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ChromoGenics has less than a year of cash runway based on current free cash flow.
  • ChromoGenics has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.5% each year.
X
Financial health checks
We assess ChromoGenics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ChromoGenics has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ChromoGenics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ChromoGenics dividends.
If you bought SEK2,000 of ChromoGenics shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ChromoGenics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ChromoGenics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OM:CHRO BTA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Sweden Building Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 247 Stocks 3.6%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1.2%
Sweden Bottom 25% Dividend Yield 25th Percentile 1.9%
Sweden Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ChromoGenics has not reported any payouts.
  • Unable to verify if ChromoGenics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ChromoGenics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ChromoGenics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ChromoGenics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ChromoGenics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ChromoGenics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ChromoGenics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jerker Lundgren
COMPENSATION SEK0
AGE 54
TENURE AS CEO 0.8 years
CEO Bio

Mr. Jerker Lundgren was Founder and Chief Executive Officer of Skandinaviska Glassystem AB since 1994. Mr. Lundgren has 20+ years of experience within the construction and glass industry, including project management. Mr. Lundgren served as Managing Director of Hancap Façade and Chief Executive Officer of Hancap’s subsiduary Skandinaviska Glassystem AB. He has been a Director at ChromoGenics AB (publ) since June 2016 and served as its Director from June 2010 to June 2015. He holds M.Sc. in Civil engineering and Construction from Lund institute of Technology.

CEO Compensation
  • Insufficient data for Jerker to compare compensation growth.
  • Jerker's remuneration is lower than average for companies of similar size in Sweden.
Management Team Tenure

Average tenure and age of the ChromoGenics management team in years:

1.6
Average Tenure
54
Average Age
  • The average tenure for the ChromoGenics management team is less than 2 years, this suggests a new team.
Management Team

Jerker Lundgren

TITLE
CEO & Director
AGE
54
TENURE
0.8 yrs

Greger Gregard

TITLE
Co-Founder & CTO
AGE
44

Lars Ericsson

TITLE
CFO & Head of Communications
AGE
61
TENURE
0.2 yrs

Micael Hamberg

TITLE
Chief Operating Officer
AGE
56
TENURE
2.3 yrs

Peter Lundh

TITLE
Head of Sales
AGE
53
TENURE
4.2 yrs
Board of Directors Tenure

Average tenure and age of the ChromoGenics board of directors in years:

1.8
Average Tenure
62.5
Average Age
  • The average tenure for the ChromoGenics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Christer Simrén

TITLE
Chairman of the Board
AGE
57
TENURE
0.6 yrs

Jerker Lundgren

TITLE
CEO & Director
AGE
54
TENURE
2.8 yrs

Anders Brännström

TITLE
Director
COMPENSATION
SEK133K
AGE
73

Claes-Göran Granqvist

TITLE
Director
COMPENSATION
SEK180K
AGE
72
TENURE
16.1 yrs

Peter Gustafson

TITLE
Director
AGE
58
TENURE
1.8 yrs

Mari Broman

TITLE
Director
AGE
67
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
X
Management checks
We assess ChromoGenics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ChromoGenics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

ChromoGenics AB provides dynamic glass with controllable heat and light transmission in Sweden and internationally. The company offers ConverLight, an electrochromic glass, which provides UV protection for use in single glass pane and insulating glass unit solutions. It serves property owners, architects, building companies, and others in the glass industry. The company was founded in 2003 and is headquartered in Uppsala, Sweden.

Details
Name: ChromoGenics AB
CHRO BTA
Exchange: OM
Founded: 2003
SEK36,278,755
43,188,995
Website: http://www.chromogenics.com
Address: ChromoGenics AB
Ullforsgatan 15,
Uppsala,
Uppsala County, 752 28,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM CHRO Common Stock OMX Nordic Exchange Stockholm SE SEK 23. Mar 2017
OM CHRO BTA NPV PAID SUBSCRIPTION SHARE BTA OMX Nordic Exchange Stockholm SE SEK 29. Jan 2019
Number of employees
Current staff
Staff numbers
28
ChromoGenics employees.
Industry
Building Products
Capital Goods
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/20 22:42
End of day share price update: 2019/03/19 00:00
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.